Site Search
Search Results
Cancer Research and Disparities: Understanding and Addressing the Issues
The COVID-19 pandemic has made clear the significant disparities that exist in our health care system and the need to address their root causes, including in cancer care. Ensuring all individuals – regardless of age, race, ethnicity, socioeconomic status, education, sexual orientation, insurance status, or ...
Community Letter Urging Congress to Enact Diagnostic Oversight Reform
Leading health care companies and organizations representing patients, providers, laboratories and diagnostic manufacturers called on Senate and House leaders to ... innovative diagnostics and clinical laboratory tests to market. In a letter to the Chairmen and Ranking members of the Senate Committee on Health, Education, Labor & Pensions (HELP) and House Energy and Commerce Committee, more than 80 organizations urged Congress to prioritize ...
Improving Access to Biomarker Testing
... from patients to identify and evaluate cancer biomarkers. Testing patients for specific biomarkers is integral to precision medicine in cancer care, but despite evidence pointing to the clinical benefits associated with biomarker testing, routine clinical use does not always follow, and ... insurance would not cover it or their out-of-pocket costs would be too high. A new report by ACS CAN and LUNGevity Foundation found while health insurance coverage for biomarker testing has improved since the organizations’ last report in 2018, coverage is still failing to keep up ... a combination of factors, as highlighted in the ACS CAN report Improving Access to Biomarker Testing - Advancing Precision Medicine in Cancer Care which explores the current landscape of cancer biomarker testing, sheds light on the nature of challenges limiting adoption of appropriate ...
Survivor Views on the Composition of Clinical Trials
... to the composition of clinical trials. Four-in-five (79%) say it is important that a drug they are prescribed has been tested in people whose health is similar to theirs, with 57% saying this is very important and 22% somewhat important. Similarly, 76% agree that it is important the drug ... important that a drug is tested in patients who share their gender. Nationality, race, and ethnicity are viewed as somewhat less important than health condition, age, and gender when it comes to trial diversity, though still important. Fifty-seven percent say it is important the drug has ... affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures. We stand with our volunteers, working to make cancer a top priority for policymakers in cities, ...
Priority Issue
State
Policy Issue
- (-) Remove Research, Funding and Drug Development filter Research, Funding and Drug Development